Health Care/Hospital Global News & Press Release Distribution

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST ProfessorJoung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea, Nov. 5, 2024 /PRNewswire/ -- On November 4, 2024, J INTS BIO hosted a significant MOU signing ceremony at Baek...

2024-11-05 17:38 1019

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

4th World Health Forum explores role of AI in global health

BEIJING, Nov. 5, 2024 /PRNewswire/ -- This is a report from China.org.cn: The Fourth World Health Forum, hosted by Tsinghua University, opened in Beijing on Saturday with the theme, "AI Empowers the Future of Health." The two-day event has brought together over 200 experts, government officials, ...

2024-11-05 16:52 984

BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral Abstract Ses...

2024-11-05 11:09 1762

111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that its release of...

2024-11-04 19:00 1761

111, Inc. Announces Change to Board of Directors

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that Dr. Leon Lian ...

2024-11-04 18:00 1665

United Imaging Healthcare Announces Q3 2024 Results with Revenue of January to September of 6.95 Billion CNY

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, announced its financial results for the third quarter of 2024. Reflecting its development strategy and strategic R&D investments, t...

2024-11-04 14:29 1389

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Nov. 2, 2024 /PRNewswire/ -- October 29, 2024, Ping An Healthcare Technology Co.,Ltd. successfully obtained the Digital Health Certificate (DHC) from the World Organization of Family Doctors (WONCA) and the WONCA Family Doctor Development & Enhancement (DEP) Certificate fo...

2024-11-03 01:39 2944

NeuroBlu: New Data Partner and Enterprise SSO Integration

Major expansion of behavioral health data with 940K+ new patient records, enterprise SSO integration, and enhanced analytics tools for deeper research insights. NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Holmusk, a global leader in behavioral health real-world evidence, today announced the release ...

2024-11-01 23:09 1593

The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved

SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by th...

2024-11-01 19:04 2403

HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

* HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of430 million KRW. * Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected inNovember 2024. ROCKVILLE, Md. and SEOUL, Sout...

2024-11-01 19:00 2312

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr.Yiu-Lian Fong to the board of directors for Din...

2024-11-01 15:28 1553

PharmaResearch Hosts 5th Global Symposium on 'Rejuran'

* Over 600 Medical Professionals from 25 Countries Participate * Launch of 'IRC' Committee for Rejuran Global Research Team SEONGNAM, South Korea, Nov. 1, 2024 /PRNewswire/ -- PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch ...

2024-11-01 14:01 1615

PharmaResearch Hosts 5th Global Symposium on 'Rejuran'

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab

HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to comp...

2024-11-01 11:34 1498

CARsgen® U.S. Clinical Holds Lifted by FDA

SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration ("FDA") lifted the clinica...

2024-11-01 09:33 1660

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") inPortugal, for exclusive rights to the commercialization of clobetasol propionate oph...

2024-10-31 21:36 1657

The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024

WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...

2024-10-31 21:00 1010

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...

2024-10-31 20:14 1399

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...

2024-10-31 20:00 1075

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...

2024-10-31 19:00 1535

Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the imm...

2024-10-31 18:00 1166